CDX, PDXOncologyLung CancerNSCLC- Lung CancerHCC827, LU1235, LU1868A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung TumorsNA2016
PDXOncologyEsophageal CancerESCC - Esophageal CancerES0026, ES0042, ES0110, ES0136, ES0141, ES0172, ES0176, ES0178, ES0191, ES0195, ES0199, ES0201, ES0204, ES0215, ES0219, ES2116A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplificationH Hanting Zhu , et al.2018
PDXOncologyAcute Myeloid LeukemiaM5 - Acute Myeloid LeukemiaAM7577AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomesNA2017
NAImmuno-Oncology, InflammationNANANAAdenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cellsNA2021
PDXOncologyAcute Myeloid LeukemiaNAAM7577AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 MutationsNA2021
CDXOncologyLung CancerNSCLC (EGFR hi) - Lung CancerHCC827Allosteric SHP2 inhibitor IACS-13909 overcomes EGFR-dependent and EGFR-independent resistance mechanisms towards osimertinibNA2020
PDXOncologyLung CancerNSCLC- Lung CancerLU0387Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 InsertionsNA2018
PDX, SygeneicOncologyGastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Melanoma, Ovarian CancerNANAAntibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in miceNA2020
NANANANANAAssessing therapy response in patient-derived xenografts.J Janosch Ortmann , et al.2021
CDX, Cell lines, Organoids, PDXNANANANAAuthentication, characterization and contamination detection of cell lines, xenografts and organoids by barcode deep NGS sequencingNA2020
NAImmuno-Oncology, InflammationNANANABrain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastasesNA2021
PDXImmuno-Oncology, OncologyBladder Cancer, Gastric Cancer, Lung CancerNANAc-Myc Alteration Determines the Therapeutic Response to FGFR InhibitorsNA2017
PDXOncologyColorectal CancerNACR0170, CR0193, CR0196, CR0231, CR0588, CR2110, CR2502, CR2520Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signatureS Sheng Guo , et al.2016
PDXImmuno-OncologyColorectal CancerMucinous adenocarcinoma - Gastric CancerCR0004, CR0010, CR0012, CR0024, CR0028, CR0029, CR0047, CR0133, CR11377Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signatureNA2017
PDXOncologyGastric CancerNAGA0060Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric CancerNA2019
NAImmuno-Oncology, InflammationNANANADifferent syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatmentNA2022
NANANANANADistinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.T Ting Liu , et al.2022
CDX, GEMMImmuno-OncologyAcute Lymphoblastic Leukemia, Adrenal gland CancerNA - Adrenal gland Cancer, T - Acute Lymphoblastic LeukemiaAD0484DNA-Damage-Induced Alternative Splicing of p53J Jing Chen , et al.2021
PDXOncologyColorectal CancerNACR2518, CR2545Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsNA2017
PDXOncologyPancreatic CancerNANAEfficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cellsNA2017
CDX, PDXOncologyLung CancerNSCLC- Lung CancerHCC827, LU0387EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF ReceptorNA2016
PDXOncologyGastric CancerNANAEGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximabX Xiaohong Wang , et al.2017
PDXImmuno-OncologyLung CancerNSCLC- Lung CancerLU0858, LU1868Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancerLA Louise A Koopman , et al.2019
PDXImmuno-Oncology, InflammationLung CancerNSCLC- Lung CancerLU2503, LU5381Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsNA2017
HuGEMM, MiXenoImmuno-Oncology, OncologyLung CancerNSCLC- Lung CancerHCC827HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic propertiesNA2020
MuPrimeOncologyPancreatic CancerDuctal adenocarcinoma - Pancreatic CancerNAImmunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow CytometryX Xiaoyu An , et al.2018
CDX, GEMM, HuCellOncologyAdrenal gland Cancer, Bladder CancerADC - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder Cancer, TCC - Bladder CancerAD0484, AL5514, AL5518, AL5521, AL8223In Vivo Pharmacology Models for Cancer Target ResearchD Dawei Chen , et al.2020
PDXOncologyKidney CancerRCC - Kidney CancerKI2367, KI2368Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft modelsB Baoan Hong , et al.2017
PDXOncologyNANANAMAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA DamageNA2021
PDXOncologyLung CancerNALU0387Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerNA2018
PDXOncologyColorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic CancerNANAMolecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitorNA2019
PDXImmuno-Oncology, OncologyGastric CancerADC - Gastric CancerGA0055MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor ActivityNA2018
OrganoidsOncologyNANANANew insights into the mechanisms underlying 5-fluorouracil-induced intestinal toxicity based on transcriptomic and metabolomic responses in human intestinal organoidsNA2021
MuPrimeOncologyBladder Cancer, Sarcoma, Skin CancerNABL6078, SA9003, SK6005Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor modelsNA2019
PDXOncologyLung CancerNSCLC- Lung CancerLU0387, LU0858, LU1235, LU1868, LU3075NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitorsM Mengmeng Yang , et al.2016
PDXOncologyColorectal CancerNACR3496, CR3547, CR3612, CR6227, MC3405Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome InhibitorNA2017
CDX, GEMM, HuCell, HuGEMM, Humanized models, MiXeno, MuPrime, Organoids, PDX, SygeneicImmuno-OncologyNANANAPreclinical pharmacology modeling of chimeric antigen receptor T therapiesNA2021
CDXNAAcute Graft versus Host DiseaseNAAD0344Resorbable and highly elastic block copolymers from 1,5-dioxepan-2-one and L-lactide with controlled tensile properties and hydrophilicity.M Maria Ryner , et al.2021
PDXOncologyColorectal CancerNACR1520, CR2502, CR2518, CR2520RET fusions observed in lung and colorectal cancers are sensitive to ponatinibNA2018
PDXOncologyColorectal CancerADC - Colorectal CancerCR2518RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesNA2020
PDXOncologyGISTNANARipretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA VariantsNA2019
CDX, HuCellNANANANARobotic Radical Cystectomy Outcomes after Intervention for Prostate Cancer.NH Neel H Patel , et al.2020
PDXOncologyColorectal CancerADC - Colorectal Cancer, NSCLC- Lung CancerCR2518, CR2545Selective RET kinase inhibition for patients with RET-altered cancersNA2018
PDXOncologyLymphomaB cell lymphoma - Lymphoma, B cell lymphoma (ABC/GCB, MYD88 L265P) - Lymphoma, NHL - Lymphoma, NHL (DLBCL, ABC) - LymphomaLY0257, LY2298Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKTNA2017
HuCell, HuGEMMImmuno-OncologyNANANASingle-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironmentNA2021
PDXOncologyColorectal CancerADC, mucinous adenocarcinoma - Colorectal Cancer, Adenocarcinoma - Colorectal CancerCR2506, CR3150Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell functionNA2016
CDX, HuGEMM, MiXenoImmuno-Oncology, InflammationBladder Cancer, Brain CancerADC - Bladder Cancer, Astrocytoma - Brain Cancer, SCC - Bladder Cancer, TCC - Bladder Cancer, Transition cell carcinoma - Bladder CancerAD0484, AD10272, AL5511, BL3249The design, analysis and application of mouse clinical trials in oncology drug developmentS Sheng Guo , et al.2019
PDXOncologySarcomaEwing's Sarcoma - SarcomaSA10233The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor ToxicityDAR Daniel A R Heisey , et al.2018
CDX, HuCellOncologyBladder CancerNA - Bladder Cancer, Sarcoma - Bladder Cancer, SCC - Bladder CancerAD0484, AL5511, BL3249The Immune Landscape of CancerV Vésteinn Thorsson , et al.2019
PDXImmuno-Oncology, OncologyLung CancerNSCLC- Lung CancerLU1147, LU11693, LU2512, LU6405The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and PatientsNA2020
PDXImmuno-Oncology, OncologyKidney CancerCCRCC - Kidney CancerNATranscriptomic characterization and innovative molecular classification of clear cell renal cell carcinoma in the Chinese populationQ Qiang Zhao , et al.2020
PDX, SygeneicImmuno-Oncology, OncologyNANANATumor Purity in Preclinical Mouse Tumor ModelsNA2022
PDXOncologyLung CancerSCLC - Lung CancerLU5263Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 ExpressionTL Timothy L Lochmann , et al.2017